CAUTION: TheraSphere PCa is an investigational device limited by United States law for investigational use only. It is not an approved treatment for prostate cancer and is not for sale.
VO90YAGER study overview
The VO90YAGER Study is a first-in-human, early feasibility study assessing the use of TheraSphere PCa Y-90 Glass Microspheres in patients with localized prostate cancer (PCa). The purpose of the VO90YAGER Study is to evaluate the safety of using TheraSphere PCa to treat prostate cancer patients. Additionally, the study will evaluate the accuracy and effectiveness of the treatment.
CAUTION: In the U.S. TheraSphere™ PCa is under an investigational device exemption for treatment of patients with prostate cancer and limited by Federal (or US) law to investigational use. The safety and effectiveness for this treatment has not been established.